Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Laura Miyares is active.

Publication


Featured researches published by Laura Miyares.


eNeuro | 2016

Mammalian FMRP S499 Is Phosphorylated by CK2 and Promotes Secondary Phosphorylation of FMRP.

Christopher M. Bartley; R. A. OKeefe; A. Blice-Baum; M.-R. Mihailescu; Xuan Gong; Laura Miyares; E. Karaca; Angélique Bordey

Visual Abstract Abstract The fragile X mental retardation protein (FMRP) is an mRNA-binding regulator of protein translation that associates with 4-6% of brain transcripts and is central to neurodevelopment. Autism risk genes’ transcripts are overrepresented among FMRP-binding mRNAs, and FMRP loss-of-function mutations are responsible for fragile X syndrome, the most common cause of monogenetic autism. It is thought that FMRP-dependent translational repression is governed by the phosphorylation of serine residue 499 (S499). However, recent evidence suggests that S499 phosphorylation is not modulated by metabotropic glutamate receptor class I (mGluR-I) or protein phosphatase 2A (PP2A), two molecules shown to regulate FMRP translational repression. Moreover, the mammalian FMRP S499 kinase remains unknown. We found that casein kinase II (CK2) phosphorylates murine FMRP S499. Further, we show that phosphorylation of FMRP S499 permits phosphorylation of additional, nearby residues. Evidence suggests that these nearby residues are modulated by mGluR-I and PP2A pathways. These data support an alternative phosphodynamic model of FMRP that is harmonious with prior studies and serves as a framework for further investigation.


Human Molecular Genetics | 2015

Activating the translational repressor 4E-BP or reducing S6K-GSK3β activity prevents accelerated axon growth induced by hyperactive mTOR in vivo

Xuan Gong; Longbo Zhang; Tianxiang Huang; Tiffany V. Lin; Laura Miyares; John H. Wen; Lawrence Hsieh; Angélique Bordey

Abnormal axonal connectivity and hyperactive mTOR complex 1 (mTORC1) are shared features of several neurological disorders. Hyperactive mTORC1 alters axon length and polarity of hippocampal neurons in vitro, but the impact of hyperactive mTORC1 on axon growth in vivo and the mechanisms underlying those effects remain unclear. Using in utero electroporation during corticogenesis, we show that increasing mTORC1 activity accelerates axon growth without multiple axon formation. This was prevented by counteracting mTORC1 signaling through p70S6Ks (S6K1/2) or eukaryotic initiation factor 4E-binding protein (4E-BP1/2), which both regulate translation. In addition to regulating translational targets, S6K1 indirectly signals through GSK3β, a regulator of axogenesis. Although blocking GSK3β activity did not alter axon growth under physiological conditions in vivo, blocking it using a dominant-negative mutant or lithium chloride prevented mTORC1-induced accelerated axon growth. These data reveal the contribution of translational and non-translational downstream effectors such as GSK3β to abnormal axon growth in neurodevelopmental mTORopathies and open new therapeutic options for restoring long-range connectivity.


Stroke | 2018

Cerebrovascular Disease Knowledge Portal: An Open-Access Data Resource to Accelerate Genomic Discoveries in Stroke

Katherine Crawford; Cristina Gallego-Fabrega; Christina Kourkoulis; Laura Miyares; Sandro Marini; Jason Flannick; Noël P. Burtt; Marcin von Grotthuss; Benjamin Alexander; Maria C. Costanzo; Neil H. Vaishnav; Rainer Malik; Jennifer L. Hall; Michael Chong; Jonathan Rosand; Guido J. Falcone

Stroke is a leading cause of death and disability across the globe, affecting 15 million people each year.1 Stroke represents an archetypical common complex disease with both genetic and environmental determinants2,3 playing a role in its occurrence. The proportion of stroke risk that can be attributed to genetic variation has been estimated to be 30%.4–6 Although this estimate provides an indication of the overall importance of genetic variation in stroke, the key to developing new treatment strategies is to identify the specific genetic variants (mutations) that modify an individual’s risk of stroke. Genetic association studies (GWAS) seek to identify these variants and link them to specific genes, which, in turn, point to specific cellular processes to become therapeutic targets for drug development. In addition, newly discovered genetic risk loci can be used to improve existing phenotyping systems, enhance prediction tools aimed to identify high-risk patients, and aid in establishing causality for associations involving nongenetic exposures. Successfully identifying the range of genetic variants that cause stroke and leveraging these discoveries to reduce the suffering caused by this condition requires overcoming several key challenges. First, stroke is the final result of multiple different pathological processes and must, therefore, be accurately subtyped to identify underlying biology. Second, because large number of cases and controls are required to identify the culprit genetic variants, tens (even hundreds) of thousands of cases must be studied, requiring the collaboration of multiple centers, many of which use different ascertainment methods and criteria. Third, because genetic variation differs across the globe, representative populations from all ethnicities must be studied. Finally, all these data must be shared rapidly and widely to ensure the most expedited progress in research and enable investigators with the brightest ideas to utilize these data provided by patients to …


Neuroscience Letters | 2017

Outbred CD1 mice are as suitable as inbred C57BL/6J mice in performing social tasks

Lawrence S. Hsieh; John H. Wen; Laura Miyares; Paul J. Lombroso; Angélique Bordey

Inbred mouse strains have been used preferentially for behavioral testing over outbred counterparts, even though outbred mice reflect the genetic diversity in the human population better. Here, we compare the sociability of widely available outbred CD1 mice with the commonly used inbred C57BL/6J (C57) mice in the one-chamber social interaction test and the three-chamber sociability test. In the one-chamber task, intra-strain pairs of juvenile, non-littermate, male CD1 or C57 mice display a series of social and aggressive behaviors. While CD1 and C57 pairs spend equal amount of time socializing, CD1 pairs spend significantly more time engaged in aggressive behaviors than C57 mice. In the three-chamber task, sociability of C57 mice was less dependent on acclimation paradigms than CD1 mice. Following acclimation to all three chambers, both groups of age-matched male mice spent more time in the chamber containing a stranger mouse than in the empty chamber, suggesting that CD1 mice are sociable like C57 mice. However, the observed power suggests that it is easier to achieve statistical significance with C57 than CD1 mice. Because the stranger mouse could be considered as a novel object, we assessed for a novelty effect by adding an object. CD1 mice spend more time in the chamber with a stranger mouse than that a novel object, suggesting that their preference is social in nature. Thus, outbred CD1 mice are as appropriate as inbred C57 mice for studying social behavior using either the single or the three-chamber test using a specific acclimation paradigm.


Stroke | 2018

17p12 Influences Hematoma Volume and Outcome in Spontaneous Intracerebral Hemorrhage

Sandro Marini; William J. Devan; Farid Radmanesh; Laura Miyares; Timothy Poterba; Björn M. Hansen; Bo Norrving; Jordi Jimenez-Conde; Eva Giralt-Steinhauer; Roberto Elosua; Elisa Cuadrado-Godia; Carolina Soriano; Jaume Roquer; Christina Kourkoulis; Alison Ayres; Kristin Schwab; David L. Tirschwell; Magdy Selim; Devin L. Brown; Scott Silliman; Bradford B. Worrall; James F. Meschia; Chelsea S. Kidwell; Joan Montaner; Israel Fernandez-Cadenas; Pilar Delgado; Steven M. Greenberg; Arne Lindgren; Charles C. Matouk; Kevin N. Sheth

Background and Purpose— Hematoma volume is an important determinant of clinical outcome in spontaneous intracerebral hemorrhage (ICH). We performed a genome-wide association study (GWAS) of hematoma volume with the aim of identifying novel biological pathways involved in the pathophysiology of primary brain injury in ICH. Methods— We conducted a 2-stage (discovery and replication) case-only genome-wide association study in patients with ICH of European ancestry. We utilized the admission head computed tomography to calculate hematoma volume via semiautomated computer-assisted technique. After quality control and imputation, 7 million genetic variants were available for association testing with ICH volume, which was performed separately in lobar and nonlobar ICH cases using linear regression. Signals with P<5×10−8 were pursued in replication and tested for association with admission Glasgow coma scale and 3-month post-ICH dichotomized (0–2 versus 3–6) modified Rankin Scale using ordinal and logistic regression, respectively. Results— The discovery phase included 394 ICH cases (228 lobar and 166 nonlobar) and identified 2 susceptibility loci: a genomic region on 22q13 encompassing PARVB (top single-nucleotide polymorphism rs9614326: &bgr;, 1.84; SE, 0.32; P=4.4×10−8) for lobar ICH volume and an intergenic region overlying numerous copy number variants on 17p12 (top single-nucleotide polymorphism rs11655160: &bgr;, 0.95; SE, 0.17; P=4.3×10−8) for nonlobar ICH volume. The replication included 240 ICH cases (71 lobar and 169 nonlobar) and corroborated the association for 17p12 (P=0.04; meta-analysis P=2.5×10−9; heterogeneity, P=0.16) but not for 22q13 (P=0.49). In multivariable analysis, rs11655160 was also associated with lower admission Glasgow coma scale (odds ratio, 0.17; P=0.004) and increased risk of poor 3-month modified Rankin Scale (odds ratio, 1.94; P=0.045). Conclusions— We identified 17p12 as a novel susceptibility risk locus for hematoma volume, clinical severity, and functional outcome in nonlobar ICH. Replication in other ethnicities and follow-up translational studies are needed to elucidate the mechanism mediating the observed association.


JAMA Neurology | 2018

Publication and Dissemination of Results in Clinical Trials of Neurology

Anirudh Sreekrishnan; David Mampre; Cora Ormseth; Laura Miyares; Audrey Leasure; Joseph S. Ross; Kevin N. Sheth


Stroke | 2018

Cerebrovascular Disease Knowledge Portal

Katherine Crawford; Cristina Gallego-Fabrega; Christina Kourkoulis; Laura Miyares; Sandro Marini; Jason Flannick; Noël P. Burtt; Marcin von Grotthuss; Benjamin Alexander; Maria C. Costanzo; Neil H. Vaishnav; Rainer Malik; Jennifer L. Hall; Michael Chong; Jonathan Rosand; Guido J. Falcone


Stroke | 2018

Abstract TP304: Stroke-Specific Quality of Life as an Independent Outcome in Intracerebral Hemorrhage

Audrey Leasure; Anirudh Sreekrishnan; Cora Ormseth; Laura Miyares; David Mampre; Chris McLaughlin; Hardik Amin; Lauren H. Sansing; Guido J. Falcone; Kevin N. Sheth


Stroke | 2018

Abstract WMP96: Racial Variation in Comfort Measures Only Status in Patients With Intracerebral Hemorrhage

Cora Ormseth; Guido J. Falcone; Sara Jasak; David Mampre; Audrey Leasure; Laura Miyares; David Y. Hwang; Michael L. James; Fernando D. Testai; Kyra J. Becker; David L. Tirschwell; Carl D. Langefeld; Daniel Woo; Kevin N. Sheth


Stroke | 2018

Abstract TP161: The Cerebrovascular Disease Knowledge Portal: an Open Access Data Resource to Accelerate Genomic Discoveries in Stroke

Katherine Crawford; Christina Kourkoulis; Laura Miyares; Noël P. Burtt; Jason Flannick; Jennifer L. Hall; Jonathan Rosand; Guido J. Falcone

Collaboration


Dive into the Laura Miyares's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Daniel Woo

University of Cincinnati

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge